Oligomerix is discovering and developing therapeutics for neurodegenerative diseases characterized by the accumulation of tau aggregates. There are over 20 tauopathies with Alzheimer’s being the most prevalent
Alzheimer’s disease is a degenerative brain disease and the most common form of dementia. It is estimated that there are 5.3 million Alzheimer’s patients in the United States in 2015 and growing rapidly expecting to triple by 2050. AD remains a major unmet medical need. It is the most costly disease in the US with a financial burden of over $226 billion annually in direct costs that are estimated to increase to $1.2 trillion by 2050 (Alzheimer’s Association, AD Facts and Figures 2015).
Given the unmet need, Oligomerix’s is focused on developing disease-modifying treatments across two key programs. The lead program is a small molecule discovery platform that inhibits the formation of tau oligomers. Oligomerix has a second program targeting tau oligomer self-truncation which has led to the development of antibodies specific for autoproteolytic tau fragments and assays that can be used to select small molecule inhibitors of tau protease activity.
The Company has also developed antibody fragments that are specific for tau oligomers. These antibodies can be used as biomarkers for the drug development programs and have potential for diagnostic and therapeutic development.